CORRECTION NOTICE “Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review”
Cacciapaglia F, Stano S, Fornaro M, Iannone F. Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review. Journal of Scleroderma and Related Disorders. 2022 Sep 28:23971983221124180.
In the above-referenced article, the following information is updated:
On page 5, in the last paragraph of the Discussion section, the following text is stated: “Noteworthy, some RCTs evaluating the role of Igs for treatment of skin involvement in dcSSc patients have been carried out and are registered on ClinicalTrials.gov. One of them, which aimed to assess the efficacy and toxicity of intravenous Ig therapy at 24 weeks (NCT04138485), was withdrawn for ethical concerns. Another RCT (NCT04137224) results are ongoing but not recruiting for the head-to-head comparison of IV versus sc Ig administration.”
The authors would like to flag that the first trial mentioned (NCT04138485) was not withdrawn for “ethical concerns” but “due to business reasons, not safety issue” as stated on the clinicaltrial.gov page (https://clinicaltrials.gov/ct2/show/NCT04138485).
Regarding the second trial (NCT04137224), the authors would like to flag that it was never designed for a head-to-head comparison but “to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis, and to evaluate the relative bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10”, as stated on the clinicaltrial.gov page (https://www.clinicaltrials.gov/ct2/show/NCT04137224).
The online version of the article has been corrected.
